These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 34271171)

  • 1. Sustained and controlled delivery of doxorubicin from an in-situ setting biphasic hydroxyapatite carrier for local treatment of a highly proliferative human osteosarcoma.
    Liu Y; Raina DB; Sebastian S; Nagesh H; Isaksson H; Engellau J; Lidgren L; Tägil M
    Acta Biomater; 2021 Sep; 131():555-571. PubMed ID: 34271171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone mineral: A trojan horse for bone cancers. Efficient mitochondria targeted delivery and tumor eradication with nano hydroxyapatite containing doxorubicin.
    Liu Y; Nadeem A; Sebastian S; Olsson MA; Wai SN; Styring E; Engellau J; Isaksson H; Tägil M; Lidgren L; Raina DB
    Mater Today Bio; 2022 Mar; 14():100227. PubMed ID: 35265825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Redox-sensitive and hyaluronic acid functionalized liposomes for cytoplasmic drug delivery to osteosarcoma in animal models.
    Chi Y; Yin X; Sun K; Feng S; Liu J; Chen D; Guo C; Wu Z
    J Control Release; 2017 Sep; 261():113-125. PubMed ID: 28666726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro evaluation of a biomaterial-based anticancer drug delivery system as an alternative to conventional post-surgery bone cancer treatment.
    Bischoff I; Tsaryk R; Chai F; Fürst R; Kirkpatrick CJ; Unger RE
    Mater Sci Eng C Mater Biol Appl; 2018 Dec; 93():115-124. PubMed ID: 30274043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-delivery of doxorubicin and paclitaxel by reduction/pH dual responsive nanocarriers for osteosarcoma therapy.
    Li Y; Hou H; Zhang P; Zhang Z
    Drug Deliv; 2020 Dec; 27(1):1044-1053. PubMed ID: 32633576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyaluronated liposomes containing H2S-releasing doxorubicin are effective against P-glycoprotein-positive/doxorubicin-resistant osteosarcoma cells and xenografts.
    Gazzano E; Buondonno I; Marengo A; Rolando B; Chegaev K; Kopecka J; Saponara S; Sorge M; Hattinger CM; Gasco A; Fruttero R; Brancaccio M; Serra M; Stella B; Fattal E; Arpicco S; Riganti C
    Cancer Lett; 2019 Aug; 456():29-39. PubMed ID: 31047947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combinational delivery of anticancer drugs for osteosarcoma treatment using electrosprayed core shell nanocarriers.
    Prasad SR; Jayakrishnan A; Kumar TSS
    J Mater Sci Mater Med; 2020 May; 31(5):44. PubMed ID: 32367204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In situ Co-Delivery of Doxorubicin and Cisplatin by Injectable Thermosensitive Hydrogels for Enhanced Osteosarcoma Treatment.
    Si M; Xia Y; Cong M; Wang D; Hou Y; Ma H
    Int J Nanomedicine; 2022; 17():1309-1322. PubMed ID: 35345787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mesenchymal Stem Cell Derived Exosomes as Nanodrug Carrier of Doxorubicin for Targeted Osteosarcoma Therapy via SDF1-CXCR4 Axis.
    Wei H; Chen F; Chen J; Lin H; Wang S; Wang Y; Wu C; Lin J; Zhong G
    Int J Nanomedicine; 2022; 17():3483-3495. PubMed ID: 35959282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pioglitazone modulates doxorubicin resistance in a in vivo model of drug resistant osteosarcoma xenograft.
    Natarajan A; Ramachandran B; Gopisetty G; Jayavelu S; Sundersingh S; Rajkumar T
    Naunyn Schmiedebergs Arch Pharmacol; 2021 Feb; 394(2):361-371. PubMed ID: 33015747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization and Evaluation of Bone-Derived Nanoparticles as a Novel pH-Responsive Carrier for Delivery of Doxorubicin into Breast Cancer Cells.
    Haque ST; Islam RA; Gan SH; Chowdhury EH
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32937817
    [No Abstract]   [Full Text] [Related]  

  • 12. Osteosarcoma cell death induced by innovative scaffolds doped with chemotherapeutics.
    Lanzillotti C; Iaquinta MR; De Pace R; Mosaico M; Patergnani S; Giorgi C; Tavoni M; Dapporto M; Sprio S; Tampieri A; Montesi M; Martini F; Mazzoni E
    J Cell Physiol; 2024 May; 239(5):e31256. PubMed ID: 38591855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-nanoencapsulated doxorubicin and Dz13 control osteosarcoma progression in a murine model.
    Tan ML; Friedhuber AM; Dass CR
    J Pharm Pharmacol; 2013 Jan; 65(1):35-43. PubMed ID: 23215686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Folic acid decorated metal-organic frameworks loaded with doxorubicin for tumor-targeted chemotherapy of osteosarcoma.
    Xu W; Lou Y; Chen W; Kang Y
    Biomed Tech (Berl); 2020 Apr; 65(2):229-236. PubMed ID: 31605575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surgery Combined with Local Implantation of Doxorubicin-Functionalized Hydroxyapatite Halts Tumor Growth and Prevents Bone Destruction in an Aggressive Osteosarcoma.
    Liu Y; Corbascio T; Huang J; Engellau J; Lidgren L; Tägil M; Raina DB
    J Funct Biomater; 2024 Aug; 15(8):. PubMed ID: 39194669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-delivery of cisplatin and doxorubicin by covalently conjugating with polyamidoamine dendrimer for enhanced synergistic cancer therapy.
    Guo XL; Kang XX; Wang YQ; Zhang XJ; Li CJ; Liu Y; Du LB
    Acta Biomater; 2019 Jan; 84():367-377. PubMed ID: 30528609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyaluronic acid modified pH-sensitive liposomes for targeted intracellular delivery of doxorubicin.
    Paliwal SR; Paliwal R; Agrawal GP; Vyas SP
    J Liposome Res; 2016 Dec; 26(4):276-87. PubMed ID: 26784587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro delivery and controlled release of Doxorubicin for targeting osteosarcoma bone cancer.
    Kamba SA; Ismail M; Hussein-Al-Ali SH; Ibrahim TA; Zakaria ZA
    Molecules; 2013 Aug; 18(9):10580-98. PubMed ID: 23999729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preparation, characterization and preliminary pharmacokinetic study of pH-sensitive Hydroxyapatite/Zein nano-drug delivery system for doxorubicin hydrochloride.
    Zha L; Wang B; Qian J; Fletcher B; Zhang C; Dong Q; Chen W; Hong L
    J Pharm Pharmacol; 2020 Apr; 72(4):496-506. PubMed ID: 31975457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EphA2 Targeted Doxorubicin-Nanoliposomes for Osteosarcoma Treatment.
    Haghiralsadat F; Amoabediny G; Naderinezhad S; Nazmi K; De Boer JP; Zandieh-Doulabi B; Forouzanfar T; Helder MN
    Pharm Res; 2017 Dec; 34(12):2891-2900. PubMed ID: 29110283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.